Published Date: 13 Mar 2023
The FDA approval request for CSU is based on data from a pair of Phase 3 trials in two different populations.
Read Full News1.
Risk of a second cancer after early breast cancer is low, say new findings
2.
MCh in Gynecologic Oncology: Admission, Medical School, Fees, Qualifications Information
3.
Don't Call It Cancer; Clues to 'Exceptional' Responses; More Predictions for 2025
4.
Photoacoustic spectral analysis for gaining knowledge of the tumor microenvironment.
5.
Survival is extended by a new treatment option for metastatic colorectal cancer.
1.
Empowering Lung Cancer Diagnosis Through the Synergy of Advanced Technologies and Artificial Intelligence
2.
Understanding Drug-Induced Cardiotoxicity: Mechanisms, Impact, and Future Directions
3.
Survivin as a Key Regulator in Gynecological Cancers: Therapeutic and Prognostic Implications
4.
Esophageal Cancer Survival Rates and Outcomes: Evidence-Based Insights from Oncology Studies
5.
Epigenetics and Resistance: Mechanisms in Histone Methylation-Targeted Therapies
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
2.
Navigating the Complexities of Ph Negative ALL - Part X
3.
Preventing Blood Clots: The Importance of Venous Thromboembolism Management
4.
Navigating the Complexities of Ph Negative ALL - Part VI
5.
Navigating the Complexities of Ph Negative ALL - Part XI
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation